CompletedPhase 2NCT04405310

Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Grupo Mexicano para el Estudio de la Medicina Intensiva
Principal Investigator
ORLANDO CARILLO-TORRES, PHD
Hospital General de Mexico Dr. Eduardo Liceaga
Intervention
Convalescent Plasma of patients with COVID-19(biological)
Enrollment
42 target
Eligibility
18-70 years · All sexes
Timeline
20202020

Study locations (2)

Collaborators

Hospital General Naval de Alta Especialidad - Escuela Medico Naval · National Institute of Pediatrics, Mexico · Instituto Nacional de Enfermedades Respiratorias

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04405310 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials